Lercanidipine Accord (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in the smooth muscle of arterial walls. This inhibition prevents calcium entry, leading to relaxation of the vascular smooth muscle, vasodilation, and a subsequent decrease in systemic vascular resistance. The reduced resistance allows blood to flow more easily, thereby lowering systolic and diastolic blood pressure.

The appropriate dose of Lercanidipine Accord is determined by the prescribing healthcare professional based on the individual patient's clinical condition, response to therapy, and any concomitant medications. Dosage adjustments are made according to therapeutic goals and tolerability, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

Safety data for lercanidipine in pregnancy and lactation are limited, and the drug is generally not recommended unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative antihypertensive options with their healthcare provider.

To place an order, visit the product page for Lercanidipine Accord on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it has a lower incidence of cough and metabolic effects but may cause more peripheral edema. Its once‑daily dosing and favorable tolerability make it a useful option, especially when patients experience side effects from other classes.

Lercanidipine Accord tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight, and excessive heat to maintain potency throughout its shelf life.

Lercanidipine Accord is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious adverse events, although rare, include severe hypotension, angioedema, myocardial infarction, hepatic dysfunction, and life‑threatening allergic reactions. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain, or signs of liver injury such as jaundice.

Lercanidipine Accord is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or acute myocardial infarction until stabilized, and in patients where safety in pregnancy or lactation cannot be assured.